Rivastigmine transdermal patch
Sponsors
Novartis Pharmaceuticals, Novartis, Inha University Hospital, Assistance Publique - Hôpitaux de Paris, VA Office of Research and Development
Conditions
Alzheimer's DiseaseCognitive ImpairmentDeliriumDementia
skin sensitization
Rivastigmine transdermal patch
DementiaDementia, Alzheimer TypeMultiple SclerosisParkinson DiseaseParkinson Disease Dementia
Phase 3
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
CompletedNCT00099242
Start: 2003-11-30End: 2006-01-31Target: 1040Updated: 2017-10-13
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
CompletedNCT00219232
Start: 2003-02-28End: 2006-07-31Updated: 2017-02-23
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
CompletedNCT00423085
Start: 2007-01-31End: 2010-04-30Updated: 2014-02-10
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
CompletedNCT00623103
Start: 2008-01-31Updated: 2011-11-28
Rivastigmine in the Management of Delirium
CompletedNCT01487317
Start: 2011-06-30End: 2016-02-29Updated: 2016-07-20
Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI
CompletedNCT01670526
Start: 2012-12-31End: 2017-09-30Updated: 2018-02-27
Phase 4
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
CompletedNCT00622713
Start: 2008-01-31End: 2009-01-31Updated: 2011-07-26
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
CompletedNCT00731224
Start: 2008-07-31End: 2011-10-31Updated: 2017-03-28
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
TerminatedNCT00881205
Start: 2009-04-30End: 2011-01-31Updated: 2012-03-12
Exelon Patch and Combination With Memantine Comparative Trial
CompletedNCT01025466
Start: 2008-12-31End: 2010-04-30Updated: 2010-05-19
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
CompletedNCT01529619
Start: 2012-03-31End: 2013-12-31Updated: 2016-11-18
Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease
CompletedNCT03840837
Start: 2019-05-02End: 2020-04-01Updated: 2023-12-20
The incidence of skin sensitization of rivastigmine transdermal patch in patients with dementia.
RecruitingTCTR20200911003
Start: 2020-09-11Target: 43Updated: 2026-08-03